Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.44 |
| ▸ | NOS2 | P35228 | 3/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | CFD | P00746 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 4/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | OGT | O15294 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502778 | 0.82 | NOS1 (0.42) | NOS1NOS2F2CFDNOS3 | |
| SCHEMBL4491356 | 0.82 | NOS1 (0.42) | NOS1NOS2F2CFDNOS3 | |
| SCHEMBL6508140 | 0.82 | ESR1 (0.44) | NOS1NOS2F2CFDNOS3 | |
| SCHEMBL4490244 | 0.80 | AR (0.45) | NOS1NOS2F2CFDNOS3 | |
| SCHEMBL6496075 | 0.80 | NOS1 (0.40) | NOS1NOS2F2CFDNOS3 | |
| SCHEMBL23137519 | 0.79 | NOS1 (0.48) | NOS1NOS2F2CFDNOS3 | |
| SCHEMBL619937 | 0.78 | F2 (0.52) | NOS1NOS2F2CFDNOS3 | |
| SCHEMBL6930556 | 0.77 | ALDH1A1 (0.41) | NOS1NOS2F2CFDNOS3 | |
| SCHEMBL5331026 | 0.77 | CDK1 (0.41) | NOS1NOS2F2CFDNOS3 | |
| SCHEMBL6496586 | 0.76 | CREBBP (0.38) | NOS1NOS2F2CFDNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524841-B2 | 4,4-disubstituted piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-28 | — | — | US | disclosed |
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| CN-100360521-C | 4,4-disubstituted piperidine derivatives having CCR3 antagonism | TEIJIN LTD (JP) | 2008-01-09 | — | — | CN | disclosed |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| CN-1665804-A | 4, 4-disubstituted piperidine derivatives having CCR3 antagonism | TEIJIN LTD (JP) | 2005-09-07 | — | — | CN | disclosed |
| CN-1659161-A | Piperidine derivatives having CCR3 antagonism | TEIJIN LTD (JP) | 2005-08-24 | — | — | CN | disclosed |
| EP-1505067-A1 | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-09 | — | — | EP | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | NOS1 2705/4885NOS2 2674/4885F2 4357/4885 |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | CCR3, CCR1, CCR4 | NOS1 2144/4885NOS2 2452/4885F2 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.